RAMSEY, the Isle of Man, May 3, 2012 /PRNewswire/ --IBS Group has been recognized as the largest provider of consulting services by two authoritative ratings IBS Group , a leading software development ...
Read more...
IBS Software Services has appointed Mr Vikash Sureka as its Chief Financial Officer. IBS Soft, based here, is a leading provider of new-generation IT solutions to the global travel, transportation and logistics industry.
Read more...
LONDON, UNITED KINGDOM-- - April is widely recognised as Irritable Bowel Syndrome awareness month. IBS could affect up to 20% of the UK population, yet many sufferers are unaware that they have IBS or ...
Read more...
SAN DIEGO, May 18, 2012 /PRNewswire/ -- Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal ...
Read more...
Irritable bowel syndrome (IBS) is hard to diagnose as well as treat, but researchers at the Sahlgrenska Academy, at the University of Gothenburg, Sweden, have discovered a way of confirming the disorder using stool samples.
Read more...
International Business Systems (IBS), a top global integrated ERP and supply chain provider, has named Doug Braun, a former RedPrairie executive with more than 30 years of supply chain experience, as chief executive officer.
Read more...
LONDON, April 25, 2012 /PRNewswire/ --Today's hectic lifestyle can mean not only an increase in stress and anxiety, but also an over-reliance on ready meals, high-fat snacks or take-away foods. All of ...
Read more...
Sucampo Pharmaceuticals announced the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA(lubiprostone) for the treatment of irritable bowel syndrome with constipation, ...
Read more...
DGAP-News: IBS AG excellence, collaboration, manufacturing / Keyword(s): DividendIBS AG excellence, collaboration, manufacturing Proposes DividendPayout of 0.15 EUR per Share09.05.2012 / 21:29Corporate NewsIBS AG Proposes Dividend Payout of 0.15 …
Read more...
Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.
Read more...